|
NASHVILLE, Tenn.--(BUSINESS WIRE)--Jan. 6, 2003--Renal Care Group, Inc. (NYSE:RCI - News) today announced that its clinical laboratory, RenaLab, has been awarded an accreditation by the Commission on Laboratory Accreditation of the College of American Pathologists (CAP), based on the results of a November 14th on-site inspection. During the inspection process, CAP evaluated more than 500 elements in the lab and found no deficiencies. Inspectors examined records and quality control of the laboratory for the preceding two years, as well as the education and qualifications of the total staff, the adequacy of the facilities, the equipment, laboratory safety, and laboratory management to determine how well the laboratory is serving patients.
Michael Burney, chief operating officer of RenaLab, noted, "the CAP is an advocate for high-quality and cost-effective medical care. We are proud to have achieved a perfect score on the inspection; achievement of a perfect score is quite rare among clinical laboratories due to the thoroughness and level of difficulty of the inspection process."
Additionally, RenaLab has been awarded special recognition as a 2002 Roche Diagnostics Center of Excellence for achieving the highest laboratory standards. RenaLab was one of nine clinical laboratories across the nation chosen for the award in recognition of its exceptional quality and pursuit of excellence. RenaLab is honored to be in the company of some of the country's most prestigious clinical laboratories in winning this highly coveted award. Roche Diagnostics is a leading supplier of clinical laboratory instruments and reagents in the United States.
Mr. Gary Brukardt, chief operating officer of Renal Care Group, commented, "RenaLab supports the laboratory needs of all of Renal Care Group's 20,000 dialysis patients in 27 states and, in 2002, RenaLab achieved a volume of approximately 7 million reportable results. I am proud of RenaLab's accomplishments and commend all our qualified associates who continually strive to achieve the highest standards in the industry. RenaLab has consistently provided crucial and accurate clinical laboratory results for our patients in a timely, efficient and accurate manner."
Renal Care Group, Inc. is a specialized dialysis services company that provides care to patients with kidney disease. The Company currently treats over 20,000 patients in more than 260 owned outpatient dialysis facilities, in addition to providing acute dialysis services at 120 hospitals. Over 6,000 associates provide services across the Company's 27-state network.
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Renal Care Group to differ materially from those expressed in or implied by the forward-looking statements, including risks related to: changes in the Medicare and Medicaid programs; risks related to the drug Epogen® (EPO); payment reductions by private insurers, hospitals or managed care organizations; compliance with health care and other applicable laws; the integration of acquired companies; and changes in the health care delivery, financing or reimbursement systems. These and other factors affecting the company are discussed in more detail in Renal Care Group's reports filed with the Securities and Exchange Commission, including Renal Care Group's annual report on Form 10-K for the year ended December 31, 2001, and Renal Care Group's quarterly reports on Form 10-Q for the quarters ended March 31, 2002, June 30, 2002 and September 30, 2002. Copies of Renal Care Group's SEC filings are available from Renal Care Group upon request.
Contact:
R. Dirk Allison
Chief Financial Officer
615.345.5588
|
Press Releases